{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:38:44Z","timestamp":1768315124172,"version":"3.49.0"},"reference-count":194,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1053\/j.ackd.2018.12.001","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T19:18:23Z","timestamp":1560367103000},"page":"185-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Changing Face of Human Immunodeficiency Virus-Mediated Kidney Disease"],"prefix":"10.1053","volume":"26","author":[{"given":"Krishna","family":"Sury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2018.12.001_bib1","first-page":"250","article-title":"Pneumocystis pneumonia--Los Angeles","volume":"30","author":"Gottlieb","year":"1981","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1053\/j.ackd.2018.12.001_bib2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM198403153101101","article-title":"Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome","volume":"310","author":"Rao","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/ki.1989.135","article-title":"Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study","volume":"35","author":"D'Agati","year":"1989","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000168011","article-title":"AIDS (HIV)-Associated nephropathy; does it exist?","volume":"9","author":"Rao","year":"1989","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/MNH.0b013e328345359a","article-title":"HIV- associated nephropathy: pathogenesis","volume":"20","author":"Medapalli","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ackd.2018.12.001_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.semnephrol.2008.08.007","article-title":"Thrombotic microangiopathy and other glomerular disorders in the HIV-infected patient","volume":"28","author":"Fine","year":"2008","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrneph.2015.216","article-title":"HIV-associated immune complex kidney disease","volume":"12","author":"Nobakht","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib8","first-page":"2660","article-title":"Kidney disease in\u00a0HIV-infected patients","volume":"17","author":"Scarpino","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1053\/j.ackd.2018.12.001_bib9","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMra1508467","article-title":"Kidney diseases associated with human immunodeficiency virus infection","volume":"377","author":"Cohen","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/ckj\/sfw104","article-title":"HIV and kidney diseases: 35 years of history and consequences","volume":"9","author":"Campos","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1053\/j.ackd.2018.12.001_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ki.2014.167","article-title":"Advances in the pathogenesis of HIV-associated kidney diseases","volume":"86","author":"Ross","year":"2014","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.semdp.2017.04.009","article-title":"HIV associated kidney diseases: Clarifying concordance between renal failure in HIV infection and histopathologic manifestations at kidney biopsy","volume":"34","author":"Ellis","year":"2017","journal-title":"Semin Diagn Pathol"},{"key":"10.1053\/j.ackd.2018.12.001_bib13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.4065\/82.9.1103","article-title":"HIV-1 infection and the kidney: an evolving challenge in HIV medicine","volume":"82","author":"de Silva","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.ackd.2018.12.001_bib14","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1016\/j.vaccine.2011.06.085","article-title":"Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review","volume":"29","author":"Girard","year":"2011","journal-title":"Vaccine"},{"key":"10.1053\/j.ackd.2018.12.001_bib15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1681\/ASN.V115856","article-title":"Chemokine receptor CCR5 and CXCR4 expression in HIV-associated kidney disease","volume":"11","author":"Eitner","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib16","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1681\/ASN.2006121307","article-title":"DEC-205-mediated internalization of HIV-1 results in the establishment of silent infection in renal tubular cells","volume":"18","author":"Hatsukari","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1681\/ASN.2010040379","article-title":"Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells","volume":"22","author":"Chen","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.virol.2012.09.009","article-title":"Tubular cell HIV-entry through apoptosed CD4 T cells: a novel pathway","volume":"434","author":"Singh","year":"2012","journal-title":"Virology"},{"key":"10.1053\/j.ackd.2018.12.001_bib19","doi-asserted-by":"crossref","first-page":"F664","DOI":"10.1152\/ajprenal.00629.2009","article-title":"DC-specific ICAM-3-grabbing nonintegrin mediates internalization of HIV-1 into human podocytes","volume":"299","author":"Mikulak","year":"2010","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1053\/j.ackd.2018.12.001_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ki.2009.366","article-title":"HIV-1 entry into human podocytes is mediated through lipid rafts","volume":"77","author":"Mikulak","year":"2010","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1681\/ASN.2011010068","article-title":"HIV-1 entry into renal epithelia","volume":"22","author":"Husain","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib22","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1681\/ASN.V11112079","article-title":"Renal epithelium is a previously unrecognized site of HIV-1 infection","volume":"11","author":"Bruggeman","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nm0502-522","article-title":"Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy","volume":"8","author":"Marras","year":"2002","journal-title":"Nat Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib24","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1073\/pnas.89.5.1577","article-title":"Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes","volume":"89","author":"Kopp","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ackd.2018.12.001_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1523-1755.2000.00152.x","article-title":"HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy","volume":"58","author":"Barisoni","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1172\/JCI119525","article-title":"Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression","volume":"100","author":"Bruggeman","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ackd.2018.12.001_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0092-8674(95)90306-2","article-title":"HIV accessory proteins: leading roles for the supporting cast","volume":"82","author":"Trono","year":"1995","journal-title":"Cell"},{"issue":"Suppl 5","key":"10.1053\/j.ackd.2018.12.001_bib28","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00002030-200100005-00004","article-title":"Recent advances in the understanding of HIV accessory protein function","volume":"15","author":"Steffens","year":"2001","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1006\/bbrc.1999.1708","article-title":"Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIV-infected cells?","volume":"267","author":"Azad","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.ackd.2018.12.001_bib30","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ki.2008.303","article-title":"HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells","volume":"74","author":"Rosenstiel","year":"2008","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib31","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/QAD.0b013e32833088a0","article-title":"HIV-1 Vpr activates the DNA damage response in renal tubule epithelial cells","volume":"23","author":"Rosenstiel","year":"2009","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/QAD.0b013e328337b0ab","article-title":"HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells","volume":"24","author":"Snyder","year":"2010","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib33","doi-asserted-by":"crossref","first-page":"11983","DOI":"10.1128\/JVI.00034-09","article-title":"FAT10: a novel mediator of Vpr-induced apoptosis in human immunodeficiency virus-associated nephropathy","volume":"83","author":"Snyder","year":"2009","journal-title":"J Virol"},{"key":"10.1053\/j.ackd.2018.12.001_bib34","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1172\/JCI3480","article-title":"HIV-1 kills renal tubular epithelial cells in\u00a0vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation","volume":"102","author":"Conaldi","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ackd.2018.12.001_bib35","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1681\/ASN.2005070692","article-title":"Role of ubiquitin-like protein FAT10 in epithelial apoptosis in renal disease","volume":"17","author":"Ross","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib36","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1097\/01.ASN.0000019642.55998.69","article-title":"HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes","volume":"13","author":"Husain","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib37","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1046\/j.1523-1755.2003.00283.x","article-title":"Critical role for Nef in HIV-1-induced podocyte dedifferentiation","volume":"64","author":"Sunamoto","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib38","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1097\/01.aids.0000191918.42110.27","article-title":"HIV-1 Nef induces dedifferentiation of podocytes in\u00a0vivo: a characteristic feature of HIVAN","volume":"19","author":"Husain","year":"2005","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib39","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1172\/JCI200421004","article-title":"Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways","volume":"114","author":"He","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ackd.2018.12.001_bib40","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1681\/ASN.2008080879","article-title":"Reduction of Stat3 activity attenuates HIV-induced kidney injury","volume":"20","author":"Feng","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib41","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1074\/jbc.M708920200","article-title":"HIV-1 Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein","volume":"283","author":"Lu","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ackd.2018.12.001_bib42","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1681\/ASN.2007050629","article-title":"HIV-1 upregulates VEGF in podocytes","volume":"19","author":"Korgaonkar","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib43","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.2005080878","article-title":"HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis","volume":"17","author":"Zuo","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib44","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0272-6386(12)80266-6","article-title":"The Familial risk of end-stage renal disease in African Americans","volume":"21","author":"Freedman","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0272-6386(99)70352-5","article-title":"Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy","volume":"34","author":"Freedman","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib46","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1086\/587994","article-title":"Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races","volume":"197","author":"Lucas","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib47","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of Trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"10.1053\/j.ackd.2018.12.001_bib48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00002030-200402200-00022","article-title":"Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study","volume":"18","author":"Lucas","year":"2004","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib49","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1093\/ndt\/gfl337","article-title":"Antiretroviral therapy in the treatment of HIV-associated nephropathy","volume":"21","author":"Atta","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2018.12.001_bib50","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/ndt\/gft010","article-title":"The clinical and histological response of HIV-associated kidney disease to antiretroviral therapy in South Africans","volume":"28","author":"Fabian","year":"2013","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2018.12.001_bib51","doi-asserted-by":"crossref","first-page":"c262","DOI":"10.1159\/000321646","article-title":"Renal disease associated with antiretroviral therapy in the treatment of HIV","volume":"118","author":"Cooper","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.ackd.2018.12.001_bib52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/ajkd.2000.9791","article-title":"Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir","volume":"36","author":"Gagnon","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/0003-4819-127-2-199707150-00004","article-title":"Crystalluria and urinary tract abnormalities associated with indinavir","volume":"127","author":"Kopp","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00126334-200302010-00004","article-title":"Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir","volume":"32","author":"Dieleman","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2018.12.001_bib55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00042307-200011000-00004","article-title":"Indinavir urolithiasis","volume":"10","author":"Wu","year":"2000","journal-title":"Curr Opin Urol"},{"key":"10.1053\/j.ackd.2018.12.001_bib56","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1053\/ajkd.2001.27732","article-title":"Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors","volume":"38","author":"Reilly","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib57","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1016\/S0272-6386(00)70034-5","article-title":"Acute tubulointerstitial nephritis attributable to indinavir therapy","volume":"35","author":"Jaradat","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib58","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/339486","article-title":"Indinavir-associated interstitial nephritis and Urothelial inflammation: clinical and Cytologic findings","volume":"34","author":"Kopp","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s15010-001-1105-y","article-title":"Papillary necrosis associated with the HIV protease inhibitor indinavir","volume":"29","author":"Dieleman","year":"2001","journal-title":"Infection"},{"key":"10.1053\/j.ackd.2018.12.001_bib60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1056\/NEJM199902043400515","article-title":"Renal atrophy associated with long-term treatment with indinavir","volume":"340","author":"Hanabusa","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib61","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archinte.162.13.1493","article-title":"Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort","volume":"162","author":"Dieleman","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ckj\/sfv015","article-title":"Atazanavir nephrotoxicity","volume":"8","author":"Hara","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1053\/j.ackd.2018.12.001_bib63","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0022-5347(05)68795-2","article-title":"Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus","volume":"161","author":"Kohan","year":"1999","journal-title":"J Urol"},{"key":"10.1053\/j.ackd.2018.12.001_bib64","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.ki.5002134","article-title":"Nephrotoxicity of antiretroviral therapy in an HIV-infected patient","volume":"71","author":"Said","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib65","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S0272-6386(04)01093-5","article-title":"Acute interstitial nephritis associated with atazanavir, a new protease inhibitor","volume":"44","author":"Brewster","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib66","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1097\/QAD.0b013e3282f17503","article-title":"Atazanavir crystal nephropathy","volume":"21","author":"Izzedine","year":"2007","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib67","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.ajkd.2017.02.376","article-title":"Atazanavir-associated crystalline nephropathy","volume":"70","author":"Santoriello","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib68","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/QAD.0b013e32813aee35","article-title":"Atazanavir-associated nephrolithiasis: cases from the US Food and drug Administration's adverse event reporting system","volume":"21","author":"Chan-Tack","year":"2007","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib69","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1086\/521930","article-title":"Urolithiasis in HIV-positive patients treated with atazanavir","volume":"45","author":"Couzigou","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000354735","article-title":"Atazanavir-induced urine crystals demonstrated by infrared spectroscopic analysis","volume":"94","author":"Inagaki","year":"2015","journal-title":"Urol Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-201565","article-title":"Recurrent nephrolithiasis associated with atazanavir use","volume":"2014","author":"Wang","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1053\/j.ackd.2018.12.001_bib72","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/cren.2017.0096","article-title":"Ureteral obstruction due to radiolucent atazanavir Ureteral stones","volume":"3","author":"Grant","year":"2017","journal-title":"J Endourol Case Rep"},{"key":"10.1053\/j.ackd.2018.12.001_bib73","doi-asserted-by":"crossref","first-page":"e0123670","DOI":"10.1371\/journal.pone.0123670","article-title":"Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?","volume":"10","author":"Gervasoni","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.ackd.2018.12.001_bib74","doi-asserted-by":"crossref","first-page":"e112836","DOI":"10.1371\/journal.pone.0112836","article-title":"Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study","volume":"9","author":"Lafaurie","year":"2014","journal-title":"PLoS One"},{"key":"10.1053\/j.ackd.2018.12.001_bib75","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3346\/jkms.2010.25.10.1427","article-title":"Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency","volume":"25","author":"Choe","year":"2010","journal-title":"J Korean Med Sci"},{"key":"10.1053\/j.ackd.2018.12.001_bib76","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMc061892","article-title":"Atazanavir urolithiasis","volume":"355","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib77","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1024\/0369-8394.95.23.949","article-title":"[Acute tubulointerstitial nephritis in HIV infection]","volume":"95","author":"Moddel","year":"2006","journal-title":"Praxis (Bern 1994)"},{"key":"10.1053\/j.ackd.2018.12.001_bib78","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0022-5347(05)65307-4","article-title":"Nelfinavir urinary stones","volume":"167","author":"Engeler","year":"2002","journal-title":"J Urol"},{"key":"10.1053\/j.ackd.2018.12.001_bib79","first-page":"555","article-title":"Renal calculi developing de novo in a patient taking saquinavir","volume":"9","author":"Green","year":"1998","journal-title":"Int J STD AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib80","first-page":"1801","article-title":"Nephrotoxicity of ritonavir","volume":"27","author":"Deray","year":"1998","journal-title":"Presse Med"},{"issue":"Suppl 1","key":"10.1053\/j.ackd.2018.12.001_bib81","first-page":"60","article-title":"Ritonavir-induced acute kidney injury: kidney biopsy findings and review of literature","volume":"75","author":"Shafi","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib82","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1093\/ndt\/gfm467","article-title":"Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review","volume":"22","author":"D'Ythurbide","year":"2007","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2018.12.001_bib83","first-page":"247","article-title":"Nucleoside analogue-induced fatal lactic acidosis in two HIV-infected patients in Singapore","volume":"42","author":"Hwang","year":"2001","journal-title":"Singapore Med J"},{"key":"10.1053\/j.ackd.2018.12.001_bib84","first-page":"151","article-title":"Lactic acidosis and antiretroviral therapy: a case report and literature review","volume":"4","author":"Marra","year":"2000","journal-title":"Braz J Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib85","first-page":"296","article-title":"Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome","volume":"52","author":"Ahmad","year":"2006","journal-title":"J Postgrad Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib86","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1086\/313594","article-title":"Lactic acidosis associated with stavudine administration: a report of five cases","volume":"30","author":"Mokrzycki","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib87","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0188-4409(02)00454-X","article-title":"Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment","volume":"34","author":"Cornejo-Juarez","year":"2003","journal-title":"Arch Med Res"},{"key":"10.1053\/j.ackd.2018.12.001_bib88","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000013610","article-title":"Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome. A case report and review of the literature","volume":"20","author":"Shaer","year":"2000","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib89","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0168-8278(99)80020-8","article-title":"Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion","volume":"30","author":"Chariot","year":"1999","journal-title":"J Hepatol"},{"key":"10.1053\/j.ackd.2018.12.001_bib90","first-page":"929","article-title":"Type B lactic acidosis in an AIDS patient treated with zidovudine","volume":"45","author":"Aggarwal","year":"1996","journal-title":"Md Med J"},{"key":"10.1053\/j.ackd.2018.12.001_bib91","first-page":"979","article-title":"[Lactic acidosis and hepatic mitochondrial changes during a treatment with zidovudine]","volume":"21","author":"Charton-Bain","year":"1997","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1053\/j.ackd.2018.12.001_bib92","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/00003246-199708000-00034","article-title":"Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature","volume":"25","author":"Sundar","year":"1997","journal-title":"Crit Care Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib93","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00007611-199904000-00015","article-title":"Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient","volume":"92","author":"Acosta","year":"1999","journal-title":"South Med J"},{"key":"10.1053\/j.ackd.2018.12.001_bib94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.amjms.2015.11.020","article-title":"Efavirenz-associated urinary Matrix stone-A rare presentation","volume":"351","author":"Khalil","year":"2016","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.ackd.2018.12.001_bib95","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00240-006-0052-6","article-title":"Efavirenz-induced urolithiasis","volume":"34","author":"Wirth","year":"2006","journal-title":"Urol Res"},{"key":"10.1053\/j.ackd.2018.12.001_bib96","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/428840","article-title":"Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment","volume":"40","author":"Gallant","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib97","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jmii.2015.08.019","article-title":"Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients","volume":"50","author":"Huang","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1053\/j.ackd.2018.12.001_bib98","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/1471-2334-13-301","article-title":"Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study","volume":"13","author":"Cao","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib99","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000441-200212000-00011","article-title":"Rapid communication: acute renal failure associated with tenofovir: Evidence of drug-induced nephrotoxicity","volume":"324","author":"Coca","year":"2002","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.ackd.2018.12.001_bib100","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1053\/ajkd.2002.36924","article-title":"Fanconi syndrome and renal failure induced by tenofovir: a first case report","volume":"40","author":"Verhelst","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib101","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1086\/368314","article-title":"Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus","volume":"36","author":"Karras","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib102","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1016\/j.jinf.2004.08.031","article-title":"Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature","volume":"51","author":"Malik","year":"2005","journal-title":"J Infect"},{"key":"10.1053\/j.ackd.2018.12.001_bib103","first-page":"357","article-title":"Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature","volume":"15","author":"Quimby","year":"2005","journal-title":"AIDS Read"},{"key":"10.1053\/j.ackd.2018.12.001_bib104","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/RHU.0b013e31819c20d8","article-title":"Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient","volume":"15","author":"Perrot","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1053\/j.ackd.2018.12.001_bib105","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/ki.2010.318","article-title":"Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities","volume":"78","author":"Herlitz","year":"2010","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib106","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1086\/379829","article-title":"Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine","volume":"37","author":"Rollot","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib107","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jinf.2017.01.010","article-title":"Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate","volume":"74","author":"Hamzah","year":"2017","journal-title":"J Infect"},{"key":"10.1053\/j.ackd.2018.12.001_bib108","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3851\/IMP2761","article-title":"Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration","volume":"19","author":"Ezinga","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1053\/j.ackd.2018.12.001_bib109","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ki.2011.124","article-title":"Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy","volume":"80","author":"Dauchy","year":"2011","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00042560-199809010-00003","article-title":"Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients","volume":"19","author":"Ruiz","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1053\/j.ackd.2018.12.001_bib111","first-page":"55","article-title":"The choice of HIV protease inhibitor: indinavir is currently the best option","volume":"8","year":"1999","journal-title":"Prescrire Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib112","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0090-9556(25)06530-4","article-title":"Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine","volume":"23","author":"Balani","year":"1995","journal-title":"Drug Metab Disposition"},{"key":"10.1053\/j.ackd.2018.12.001_bib113","first-page":"194","article-title":"Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria","volume":"50","author":"Perazella","year":"1998","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/135965350000500105","article-title":"Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection","volume":"5","author":"Malavaud","year":"2000","journal-title":"Antivir Ther"},{"key":"10.1053\/j.ackd.2018.12.001_bib115","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/jac\/48.3.355","article-title":"Incidence and risk factors for the development of indinavir-associated renal complications","volume":"48","author":"Herman","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2018.12.001_bib116","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/430257","article-title":"Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America","volume":"40","author":"Gupta","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib117","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.ackd.2009.07.009","article-title":"Antiretroviral medications: adverse effects on the kidney","volume":"17","author":"Jao","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib118","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/aid.2014.0134","article-title":"Disappearance of renal stones in an HIV-1-infected patient after reduction of atazanavir dose","volume":"30","author":"Lanzafame","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1053\/j.ackd.2018.12.001_bib119","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1093\/jac\/dku304","article-title":"Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study","volume":"69","author":"Nishijima","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2018.12.001_bib120","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1177\/0956462414523259","article-title":"High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece","volume":"25","author":"Panagopoulos","year":"2014","journal-title":"Int J STD AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib121","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/QAD.0b013e328011d7c1","article-title":"Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia","volume":"21","author":"Rodriguez-Novoa","year":"2007","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib122","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1089\/aid.2011.0261","article-title":"Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil","volume":"28","author":"Turatti","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1053\/j.ackd.2018.12.001_bib123","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/FPC.0000000000000034","article-title":"Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202","volume":"24","author":"Johnson","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.1053\/j.ackd.2018.12.001_bib124","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","article-title":"Association of tenofovir exposure with kidney disease risk in HIV infection","volume":"26","author":"Scherzer","year":"2012","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","article-title":"Greater tenofovir-associated renal function decline with protease inhibitor-based versus Nonnucleoside reverse-transcriptase inhibitor-based therapy","volume":"197","author":"Goicoechea","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib126","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/135965350701200110","article-title":"Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir\/ritonavir","volume":"12","author":"Gerard","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1053\/j.ackd.2018.12.001_bib127","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1468-1293.2006.00349.x","article-title":"Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy","volume":"7","author":"Winston","year":"2006","journal-title":"HIV Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib128","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","article-title":"Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients","volume":"24","author":"Mocroft","year":"2010","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib129","doi-asserted-by":"crossref","first-page":"e3780","DOI":"10.1097\/MD.0000000000003780","article-title":"Estimated glomerular filtration rate Trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or Abacavir","volume":"95","author":"Gianotti","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.ackd.2018.12.001_bib130","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/QAD.0b013e32832c96e9","article-title":"Renal function with use of a tenofovir-containing initial antiretroviral regimen","volume":"23","author":"Gallant","year":"2009","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib131","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/00002030-200206140-00008","article-title":"Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study","volume":"16","author":"Schooley","year":"2002","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib132","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2018.12.001_bib133","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/ndt\/gfh658","article-title":"Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study","volume":"20","author":"Izzedine","year":"2005","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2018.12.001_bib134","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib135","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib136","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1517\/14740338.6.2.155","article-title":"Tenofovir-induced kidney injury","volume":"6","author":"Gitman","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1053\/j.ackd.2018.12.001_bib137","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/apc.2016.0286","article-title":"Effect of tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate Decrement in HIV-1-Infected treatment-naive Asian patients: results from 12-year Observational cohort","volume":"31","author":"Suzuki","year":"2017","journal-title":"AIDS Patient Care STDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib138","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjmed.2004.03.025","article-title":"Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure","volume":"117","author":"Rifkin","year":"2004","journal-title":"The Am J Med"},{"key":"10.1053\/j.ackd.2018.12.001_bib139","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/labinvest.2011.48","article-title":"Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters","volume":"91","author":"Kohler","year":"2011","journal-title":"Lab Invest"},{"key":"10.1053\/j.ackd.2018.12.001_bib140","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1128\/AAC.00251-06","article-title":"Mechanism of active renal tubular efflux of tenofovir","volume":"50","author":"Ray","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2018.12.001_bib141","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/ki.2008.252","article-title":"Rosiglitazone reverses tenofovir-induced nephrotoxicity","volume":"74","author":"Liborio","year":"2008","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib142","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/labinvest.2009.14","article-title":"Tenofovir renal toxicity targets mitochondria of renal proximal tubules","volume":"89","author":"Kohler","year":"2009","journal-title":"Lab Invest"},{"key":"10.1053\/j.ackd.2018.12.001_bib143","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-61779-163-5_22","article-title":"Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment","volume":"755","author":"Kohler","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1053\/j.ackd.2018.12.001_bib144","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/QAI.0b013e3181a666eb","article-title":"Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats","volume":"51","author":"Lebrecht","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2018.12.001_bib145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1423-0127-20-61","article-title":"Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney","volume":"20","author":"Abraham","year":"2013","journal-title":"J Biomed Sci"},{"key":"10.1053\/j.ackd.2018.12.001_bib146","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1086\/499048","article-title":"Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions","volume":"42","author":"Zimmermann","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib147","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/508546","article-title":"Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy","volume":"194","author":"Izzedine","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib148","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/FPC.0000000000000110","article-title":"A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome","volume":"25","author":"Dahlin","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"10.1053\/j.ackd.2018.12.001_bib149","first-page":"184","article-title":"Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys?","volume":"18","author":"Aloy","year":"2016","journal-title":"AIDS Rev"},{"key":"10.1053\/j.ackd.2018.12.001_bib150","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3851\/IMP2770","article-title":"Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does\u00a0not exhibit OAT-dependent cytotoxicity","volume":"19","author":"Bam","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1053\/j.ackd.2018.12.001_bib151","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01834-15","article-title":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors","volume":"60","author":"Birkus","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2018.12.001_bib152","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2018.12.001_bib153","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/jac\/dkt532","article-title":"Phase I\/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults","volume":"69","author":"Markowitz","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2018.12.001_bib154","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2018.12.001_bib155","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2018.12.001_bib156","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study","volume":"69","author":"Mills","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2018.12.001_bib157","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib158","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","article-title":"Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study","volume":"71","author":"Pozniak","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2018.12.001_bib159","doi-asserted-by":"crossref","first-page":"e8046","DOI":"10.1097\/MD.0000000000008046","article-title":"Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report","volume":"96","author":"Novick","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.ackd.2018.12.001_bib160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijid.2016.10.004","article-title":"HIV and aging","volume":"53","author":"Wing","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib161","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1093\/ndt\/gfr192","article-title":"Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis","volume":"26","author":"Lopes","year":"2011","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2018.12.001_bib162","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2369-14-32","article-title":"Long-term risk of mortality for acute kidney injury in HIV-infected patients: a cohort analysis","volume":"14","author":"Lopes","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib163","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ki.2010.171","article-title":"Long-term clinical consequences of acute kidney injury in the HIV-infected","volume":"78","author":"Choi","year":"2010","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib164","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/0272-6386(95)90490-5","article-title":"Pattern of glomerular involvement in human immunodeficiency virus-infected patients: an Italian study","volume":"26","author":"Casanova","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/oxfordjournals.ndt.a092263","article-title":"Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals","volume":"8","author":"Nochy","year":"1993","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2018.12.001_bib166","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5414\/CNP72038","article-title":"Glomerular lesions in HIV-positive patients: a 20-year biopsy experience from Northern Italy","volume":"72","author":"Nebuloni","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib167","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2215\/CJN.10991012","article-title":"Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy","volume":"8","author":"Foy","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib168","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ki.1993.386","article-title":"HIV-associated immune-mediated renal disease","volume":"44","author":"Kimmel","year":"1993","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib169","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ndt\/5.7.489","article-title":"Absence of HIV antigens in renal tissue from patients with HIV-associated nephropathy","volume":"5","author":"Barbiano di Belgiojoso","year":"1990","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2018.12.001_bib170","first-page":"61","article-title":"IgA nephritis in HIV-positive patients: a new HIV-associated nephropathy?","volume":"38","author":"Katz","year":"1992","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib171","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2005.00215.x","article-title":"HIV-associated immune complex glomerulonephritis with \u201clupus-like\u201d features: a clinicopathologic study of 14 cases","volume":"67","author":"Haas","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib172","first-page":"4467","article-title":"A case of lupus-like glomerulonephritis in an HIV patient with nephrotic range proteinuria, purpura, and elevated IgA level","volume":"7","author":"Yang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1053\/j.ackd.2018.12.001_bib173","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5414\/CNP60187","article-title":"Lupus-like nephritis in an HIV-positive patient: report of a case and review of the literature","volume":"60","author":"Tabechian","year":"2003","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib174","first-page":"769","article-title":"HIV-associated immune complex glomerulonephritis with \u201clupus-like\u201d features","volume":"22","author":"Pakasa","year":"2011","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1053\/j.ackd.2018.12.001_bib175","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0272-6386(12)80358-1","article-title":"Remission of hepatitis B-associated membranous glomerulonephritis in human immunodeficiency virus infection","volume":"17","author":"Schectman","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib176","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0272-6386(97)90332-2","article-title":"Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus","volume":"29","author":"Stokes","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib177","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1681\/ASN.V1071566","article-title":"Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection","volume":"10","author":"Cheng","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib178","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/QAD.0b013e32832ac36a","article-title":"Kidney diseases in HIV\/HCV-co-infected patients","volume":"23","author":"Izzedine","year":"2009","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2018.12.001_bib179","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5414\/CNP57154","article-title":"Type I membranoproliferative glomerulonephritis in an HIV-infected individual without hepatitis C co-infection","volume":"57","author":"Chidambaram","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib180","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1053\/j.ajkd.2003.08.034","article-title":"Immunotactoid glomerulopathy in an HIV-positive African-American man","volume":"42","author":"Martin","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib181","first-page":"80","article-title":"An uncommon glomerular disease in an HIV patient: value of renal biopsy and review of the literature","volume":"75","author":"Chen","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2018.12.001_bib182","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1523-1755.2004.00865.x","article-title":"The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection","volume":"66","author":"Szczech","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2018.12.001_bib183","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1093\/ndt\/gfr702","article-title":"The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations","volume":"27","author":"Wearne","year":"2012","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2018.12.001_bib184","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/ndt\/gfv436","article-title":"Clinical characteristics and outcomes of HIV-associated immune complex kidney disease","volume":"31","author":"Booth","year":"2016","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2018.12.001_bib185","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1086\/344778","article-title":"Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy","volume":"35","author":"Gervasoni","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib186","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.thromres.2013.08.016","article-title":"Chronic HIV disease and activation of the Coagulation system","volume":"132","author":"Baker","year":"2013","journal-title":"Thromb Res"},{"key":"10.1053\/j.ackd.2018.12.001_bib187","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.revmed.2011.11.015","article-title":"Human immunodeficiency virus-associated thrombotic microangiopathies","volume":"33","author":"Gilardin","year":"2012","journal-title":"Rev Med Interne"},{"key":"10.1053\/j.ackd.2018.12.001_bib188","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jca.20189","article-title":"ADAMTS13 activity levels in patients with human immunodeficiency virus-associated thrombotic microangiopathy and profound CD4 deficiency","volume":"24","author":"Park","year":"2009","journal-title":"J Clin Apher"},{"key":"10.1053\/j.ackd.2018.12.001_bib189","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13256-016-0938-z","article-title":"Thrombotic microangiopathy as first manifestation of acute human immunodeficiency virus infection: a case report and review of the literature","volume":"10","author":"Sarmiento","year":"2016","journal-title":"J Med Case Rep"},{"key":"10.1053\/j.ackd.2018.12.001_bib190","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2011.08636.x","article-title":"Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy","volume":"153","author":"Hart","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1053\/j.ackd.2018.12.001_bib191","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0272-6386(96)90477-1","article-title":"Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy","volume":"28","author":"Briggs","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2018.12.001_bib192","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2004.05325.x","article-title":"Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy","volume":"128","author":"Novitzky","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.ackd.2018.12.001_bib193","first-page":"145","article-title":"Thrombotic microangiopathy syndrome as an AIDS-defining illness: the experience of J. Stroger Hospital of Cook County","volume":"4","author":"Tamkus","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1053\/j.ackd.2018.12.001_bib194","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/ckj\/sfw035","article-title":"Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab","volume":"9","author":"Jin","year":"2016","journal-title":"Clin Kidney J"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154855951830243X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154855951830243X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:01:50Z","timestamp":1761548510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154855951830243X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":194,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S154855951830243X"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2018.12.001","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Changing Face of Human Immunodeficiency Virus-Mediated Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}